Company / R&D Expense
Spero Therapeutics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$96.8M
FY2025
5-year range
$47.6M / $96.8M
FY2021-FY2025
Trend
+88.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $48M to $97M over the past 2 years.
Based on SEC 10-K filings.
$97M in FY2025 with a 5-year CAGR of +8.0%.
Improved from $48M to $97M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +14.5%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +8.0%, indicating consistent growth.
- In FY2025, r&d expense increased 88.1% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $96.8M | +88.1% |
| FY2024 | $51.4M | +8.1% |
| FY2023 | $47.6M | -26.2% |
| FY2022 | $64.5M | -3.7% |
| FY2021 | $67.0M | +1.9% |
| FY2020 | $65.8M | +94.1% |
| FY2019 | $33.9M | +28.7% |
| FY2018 | $26.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026